Skip to main content
SpringerLink
Log in

Prostate cancer diagnosis, staging and survival

  • Chapter
Prostate Cancer: New Horizons in Research and Treatment

Part of the book series: Developments in Oncology ((DION,volume 81))

Summary

Prostate cancer is the most common malignancy in men and the second most common cancer related death. Through research, we have found that African-American men and men with a family history of prostate cancer have a significantly higher risk of prostate cancer. In the 90’s the mortality rate from prostate cancer decreased, presumably due to PSA testing. Patients with organ-confined tumors, particularly if they have a moderate Gleason score have an excellent chance of long-term survival with radical prostatectomy or external beam radiation therapy. Advances in detecting micrometastatic disease are needed to further impact on this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aus G. Hugosson J, Norlen L: Long-term survival among men with conservatively treated localized prostate cancer. J Urol 154: 460–465, 1995

    PubMed  CAS  Google Scholar 

  2. Ries LAG, Hankey BF, Miller BA: Cancer Statistics Review 1973–1988. Bethesda: National Cancer Institute (NIH Publication No. 91-2789), 1991

    Google Scholar 

  3. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK (eds) SEER Cancer Statistics Review, 1973–1991:TablesandGraphs.Bethesda: NationalCancer Institute, 371(NIHPublicationNo.94-2789.), 1994

    Google Scholar 

  4. Schwartz KL, Severson RK, Gurney JG, Montie JE: Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973–1994. Cancer 15: 1260–1266, 1996

    Google Scholar 

  5. Wilt TJ, Partin MR, Liang BA: Outcome-based practice: Early detection and treatment of prostate cancer. Hosp Phys 37(2): 54–67, 2001

    Google Scholar 

  6. Labrie F, Dupont A, Candas B: Decrease of prostate cancer death by screening: First data from the Quebec prospective and randomized study. Proc Am Soc Clin Oncol, 1998, Los Angeles, California.

    Google Scholar 

  7. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948–954, 1993

    PubMed  CAS  Google Scholar 

  8. Bartsch G, Horninger W, Klocker H, Oberaigner W, Severi G, Robertson C, Boyle P: Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria. (Abstract) J Urol 163(Suppl 4): 88, Abstract 387, 2000

    Google Scholar 

  9. American Foundation for Urologic Disease. Prostate cancer resource guide. 1999–2000 edition. http://www.afud.org/pca/pcaindex.html accessed Dec 16, 2001

  10. Mettlin C, Jones G, Averett H, Gusberg SB, Murphy GP: Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancers. CA Cancer J Clin 43: 42–46, 1993

    PubMed  CAS  Google Scholar 

  11. Pienta KJ, Esper RS: Risk factors for prostate cancer: Ann Intern Med 118: 793–803, 1993

    PubMed  CAS  Google Scholar 

  12. Ries LA, Kosary CL, Hankey BF: SEER cancer statistics review, 1973–1994; tables and graphs. Bethesda (MD); US National Cancer Institute; NIH Publication No. 97-2789, 1997

    Google Scholar 

  13. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H: Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 20: 680–688, 1977

    PubMed  CAS  Google Scholar 

  14. Edwards CN, Steinthorsson E, Nicholson D: An autopsy study of latent prostatic cancer. Cancer 6: 531–554, 1953

    PubMed  CAS  Google Scholar 

  15. Halpert B, Schmalhorst WR: Carcinoma of the prostate in patients 70 to 79 years old. Cancer 19: 695–698, 1966

    PubMed  CAS  Google Scholar 

  16. Scott R Jr, Mutchnik DL, Laskowski TZ, Schmalhorst WR: Carcinoma of the prostate in elderly men: Incidence, growth characteristics and clinical significance. J Urol 101(4): 602–607, 1969

    PubMed  Google Scholar 

  17. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379–385, 1993

    PubMed  CAS  Google Scholar 

  18. Parker SL, Davis KJ, Wingo PA, Ries LA, Heath CW Jr.: Cancer Statistics by Race and Ethnicity. CA Cancer J Clin 48(1): 31–48, 1998

    Article  PubMed  CAS  Google Scholar 

  19. Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR: Familial patterns of prostate cancer: A case-control analysis. JUrol 146(5): 1305–1307, 1991

    CAS  Google Scholar 

  20. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274(5291): 1371–1374, 1996

    Article  PubMed  CAS  Google Scholar 

  21. Gronberg H, Smith J, Emanuelsson M, Jonsson BA, Bergh A, Carpten J, Isaacs W, Xu J, Meyers D, Trent J, Damber JE: In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome lq2-25 is restricted to families with early-onset prostate cancer. Am J Hum Genet 65(1): 134–140, 1999

    PubMed  CAS  Google Scholar 

  22. Gronberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, Meyers DA, Collins FS, Trent JM, Walsh PC, Isaacs WB: Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 278(15): 1251–1255, 1997

    Article  PubMed  CAS  Google Scholar 

  23. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Trent J: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 20(2): 175–179, 1998

    Article  PubMed  CAS  Google Scholar 

  24. Gann, PH: Diet and prostate cancer risk: The embarrassment of riches. Cancer Causes Control 9: 541–543, 1998

    Article  PubMed  CAS  Google Scholar 

  25. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, Badalament R, Babaian R: Cost effective prostate cancer detection. Cancer 74(12): 3146–3158, 1994

    PubMed  CAS  Google Scholar 

  26. Candas B, Cusan L, Gomez J-L, Diamond P, Suburu RE, Levesque J, Brousseau G, Bclanger A, Labrie F: Evaluation of prostate specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 45(1): 19–35, 2000

    Article  PubMed  CAS  Google Scholar 

  27. Gerber GS, Thompson IM, Thisted R, Chodak GW: Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 269(1): 61–64, 1993

    Article  PubMed  CAS  Google Scholar 

  28. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL: Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 42(4): 365–374, 1993

    PubMed  CAS  Google Scholar 

  29. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA: Patterns of progression in prostate cancer. Lancet 1(8472): 60–63, 1986

    PubMed  CAS  Google Scholar 

  30. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. NEnglJ Med 324(17): 1156–1161, 1991

    CAS  Google Scholar 

  31. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 151(5): 1283–1290,1994

    PubMed  CAS  Google Scholar 

  32. Pedersen KV, Carlsson P, Varenhorst E, Lofman O, Berglund K: Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 300(6731): 1041–1044, 1990

    Article  PubMed  CAS  Google Scholar 

  33. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. American College of Physicians. Ann Intern Med 126(5): 394–406, 1997

    PubMed  CAS  Google Scholar 

  34. Elgamal AA, Van de Voorde W, Van Poppel H, Lauweryns J, Baerl L: Immunihistochemical localization of prostate-specific markers within the accessory male sex glands of Cowper, Littre, and Morgagni. Urol 44(1): 84–90, 1994

    Article  PubMed  CAS  Google Scholar 

  35. Andriole GL, Catalona WJ: Using PSA to screen for prostate cancer: The Washington University experience. Urol Clin North Am 20(4): 647–651, 1993

    PubMed  CAS  Google Scholar 

  36. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147 (3 Pt 2): 841–845, 1992

    PubMed  CAS  Google Scholar 

  37. Oesterling JE: Prostate-specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907–923, 1991

    PubMed  CAS  Google Scholar 

  38. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, de Kernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC: Use of the percentage free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 279(19): 1542–1547, 1998

    Article  PubMed  CAS  Google Scholar 

  39. Semjonow A, Hamm M, Rathert P, Hertle L: Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer. Br J Urol 73(5): 538–543, 1994

    Article  PubMed  CAS  Google Scholar 

  40. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267(16): 2215–2220, 1992

    Article  PubMed  CAS  Google Scholar 

  41. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men: Established of age-specific reference ranges. JAMA 270(7): 860–864, 1993

    Article  PubMed  CAS  Google Scholar 

  42. Moul JW: Use, Interpretation, and Prognostic Value of Total and Free PSA tests. Mediguide Urol 12(2): 1–8, 1999

    Google Scholar 

  43. Powell IJ, Banerjee M, Novallo M, Sakr W, Grignon D, Wood DP, Pontes JE: Should the age specific prostate specific antigen cutoff for prostate cancer biopsy be higher for black than for white men older than 50 years? J Urol 163(1): 146–149, 2000

    PubMed  CAS  Google Scholar 

  44. Smith DS, Catalona, WJ, Bullock AD: Lower total PSA cutoffs for cancer screening in African American men. Urol 157(suppl): 160 Abstract No. 618, 1997

    Google Scholar 

  45. Schwartz KL, Grignon DJ, Sakr WA, Wood DP Jr: Prostate cancer histologic trends in the metropolitan Detroit area, 1982 to 1996, Urology 53(4): 769–774,1999

    Article  PubMed  CAS  Google Scholar 

  46. Aarnink RG, Beerlage, HP, De La Rosette JJ, Debruyne FM, Wijkstra H: Transrectal ultrasound of the prostate: innovations and future applications. J Urol 159: 1568–1579, 1998

    Article  PubMed  CAS  Google Scholar 

  47. Halpern EJ, Strup SE: Using gray-scale and color and power Dopier sonography to detect prostatic cancer. AJR Am J Roentgenol 174(3): 623–627, 2000

    PubMed  CAS  Google Scholar 

  48. Chang JJ, Shinohara K, Bhargava V, Presti JC Jr: Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 160 (6 Pt 1): 2111–2114, 1998

    PubMed  CAS  Google Scholar 

  49. Davis GL: Sensitivity of frozen section examination of pelvic lymph nodes for metastatic prostate carcinoma. Cancer 76: 661–668, 1995

    PubMed  CAS  Google Scholar 

  50. Tiguert R, Gheiler EL, Tefilli MV, Oskanian P, Banerjee M, Grignon DJ, Sakr W, Pontes JE, Wood DP Jr: Lymph node size does not correlate with the presence of prostate cancer matastasis. Urology 53(2): 367–371, 1999

    Article  PubMed  CAS  Google Scholar 

  51. Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, Spirnak JP, Carlin B, Bellon EM, Rogers B: Preliminary imaging results using IN-III labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. Clin Nucl Med 21(10): 759–769, 1996

    Article  PubMed  CAS  Google Scholar 

  52. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE: Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 145(2): 313–318, 1991

    PubMed  CAS  Google Scholar 

  53. Wood DP, Banerjee M: Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease free survival. J Clin Oncol 15(12): 3451–3457, 1997

    PubMed  Google Scholar 

  54. Gao CL, Dean RC, Pinto A, Mooneyhan R, Connelly RR, McLeod DG, Srivastava S, Moul JW: Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. J Urol 161(4): 1070–1076, 1999

    PubMed  CAS  Google Scholar 

  55. Cher ML, de Oliveira JG, Beaman AA, Nemeth JA, Hussain M, Wood DP Jr: Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer. Clin Cancer Res 5(9): 2421–2425, 1999

    PubMed  CAS  Google Scholar 

  56. Bianco FJ Jr, Wood DP Jr, Gomes de Oliveira J, Nemeth JA, Beaman AA, Cher ML: Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate 49(4): 235–242, 2001

    Article  PubMed  Google Scholar 

  57. Ogura K, Maekawa S, Okubo K, Aoki Y, Okada T, Oda K, Watanabe Y, Tsukayam C, Arai Y: Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: Correlation with histopathologic results. Urology 57: 721–726, 2001

    Article  PubMed  CAS  Google Scholar 

  58. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC: The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150(1): 110–114, 1993

    PubMed  CAS  Google Scholar 

  59. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P, O’Dowd GJ, Veltri RW: An algorithm for predicting non-organ confined prostate cancer using the results obtained from sextant core biopsies with prostate-specific antigen level. J Urol 156(4): 1375–1380, 1996

    PubMed  CAS  Google Scholar 

  60. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage of logical prostate cancer. JAMA 277(18): 1445–1451, 1997.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Wayne State University School of Medicine and The Prostate Program of The Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    Vivek Narain, Michael L. Cher & David P. Wood Jr.

Authors
  1. Vivek Narain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael L. Cher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David P. Wood Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    Michael L. Cher

  2. Wayne State University School of Medicine, Detroit, MI, USA

    Avraham Raz  & Kenneth V. Honn  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Kluwer Academic Publishers

About this chapter

Cite this chapter

Narain, V., Cher, M.L., Wood, D.P. (2002). Prostate cancer diagnosis, staging and survival. In: Cher, M.L., Raz, A., Honn, K.V. (eds) Prostate Cancer: New Horizons in Research and Treatment. Developments in Oncology, vol 81. Springer, Boston, MA. https://doi.org/10.1007/0-306-48143-X_16

Download citation

  • DOI: https://doi.org/10.1007/0-306-48143-X_16

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-7352-6

  • Online ISBN: 978-0-306-48143-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation